Skip to main content

Severe Cutaneous Sarcoid Treated with Tofacitinib

Jan 02, 2019 12:05 pm

Researchers from Yale have taken a novel approach and shown benefits when using tofacitinib in severe cutaneous sarcoidosis.

A report in the NEJM describes a 48-year-old female woman who was previously unresponsive to multiple medications and had not received systemic glucocorticoids. She was treated with tofacitinib 10 mg twice-daily and clinically responded with near disappearance of her skin lesions..

There is biologic rationale for this approach as JAK- STAT signaling plays a role in the pathogenesis of sarcoidosis. The authors performed RNA sequencing on biopsied lesions before and during treatment, showing evidence of the Jak-STAT pathway is going from active to inactive. This, coupled with clinical and histologic remission of her skin disease suggests the potential benefit of tofacitinib.


The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.